Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt Sells 1,421 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 1,421 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total value of $132,621.93. Following the transaction, the chief financial officer owned 42,127 shares in the company, valued at $3,931,712.91. This trade represents a 3.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mirum Pharmaceuticals Price Performance

Mirum Pharmaceuticals stock opened at $94.29 on Friday. The stock has a market capitalization of $4.85 billion, a P/E ratio of -109.64 and a beta of 0.48. The company’s fifty day moving average price is $77.33 and its 200 day moving average price is $70.64. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. Mirum Pharmaceuticals, Inc. has a 1 year low of $36.88 and a 1 year high of $96.84.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The business had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. During the same period last year, the firm posted ($0.30) earnings per share. The company’s revenue was up 47.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Institutional Trading of Mirum Pharmaceuticals

Several large investors have recently added to or reduced their stakes in MIRM. Sumitomo Mitsui Trust Group Inc. purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth $240,000. Wetzel Investment Advisors Inc. acquired a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $205,000. Palumbo Wealth Management LLC raised its stake in Mirum Pharmaceuticals by 19.8% during the fourth quarter. Palumbo Wealth Management LLC now owns 5,082 shares of the company’s stock worth $401,000 after purchasing an additional 840 shares during the period. Secure Asset Management LLC raised its stake in Mirum Pharmaceuticals by 4.0% during the fourth quarter. Secure Asset Management LLC now owns 50,384 shares of the company’s stock worth $3,980,000 after purchasing an additional 1,943 shares during the period. Finally, SG Americas Securities LLC acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at about $1,478,000.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
• Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
• Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
• Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
• Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert

Wall Street Analysts Forecast Growth

MIRM has been the subject of several research reports. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $102.00 price target (up from $81.00) on shares of Mirum Pharmaceuticals in a research note on Tuesday, January 13th. Morgan Stanley boosted their price target on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Finally, Robert W. Baird raised their price objective on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $102.58.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.